openPR Logo
Press release

Allergic Rhinitis Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharma

01-16-2025 07:39 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Allergic Rhinitis Pipeline 2024: Mechanism of Action, Route

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Allergic Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Allergic Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Allergic Rhinitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Allergic Rhinitis Market.

The Allergic Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Allergic Rhinitis Pipeline Report: https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Allergic Rhinitis treatment therapies with a considerable amount of success over the years.
• Allergic Rhinitis companies working in the treatment market are Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others, are developing therapies for the Allergic Rhinitis treatment
• Emerging Allergic Rhinitis therapies in the different phases of clinical trials are- EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others are expected to have a significant impact on the Allergic Rhinitis market in the coming years.
• In June 2024, Neurent Medical, a company at the forefront of developing non-surgical treatments for chronic inflammatory sinonasal conditions, today announced the publication of positive 12-month outcomes from the CLARITY clinical trial in Laryngoscope Investigative Otolaryngology. The study shows that treatment using Neurent Medical's NEUROMARK® radiofrequency (RF) ablation device is safe and leads to sustained, significant improvements in rhinitis symptoms and quality of life throughout the 12-month follow-up period.

Allergic Rhinitis Overview
Allergic rhinitis, commonly known as hay fever, is an inflammatory condition of the nasal passages caused by an allergic reaction to airborne allergens. These allergens can include pollen, mold spores, dust mites, animal dander, and certain air pollutants. When individuals with allergic rhinitis come into contact with these triggers, their immune system releases chemicals, such as histamines, leading to symptoms.

Get a Free Sample PDF Report to know more about Allergic Rhinitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Allergic Rhinitis Drugs Under Different Phases of Clinical Development Include:
• FPP004: Funpep
• INI 2004: Inimmune
• TQC 3564: Chia Tai Tianqing Pharmaceutical Group
• ILT-101: Iltoo Pharma
• IRL201104: Revolo Biotherapeutics
• PA9159: Anhui Palo Alto Pharmaceuticals
• MM09-MG01: Immunotek SL
• AI201901: Abdi Ibrahim Pharmaceuticals
• REGN1908-1909: Regeneron
• Glycopyranosyl lipid adjuvant: Revelation Biosciences
• QX 005N: Qyuns Therapeutics
• HY-083: Hyloris Pharmaceuticals

Allergic Rhinitis Route of Administration
Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Allergic Rhinitis Molecule Type
Allergic Rhinitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Allergic Rhinitis Pipeline Therapeutics Assessment
• Allergic Rhinitis Assessment by Product Type
• Allergic Rhinitis By Stage and Product Type
• Allergic Rhinitis Assessment by Route of Administration
• Allergic Rhinitis By Stage and Route of Administration
• Allergic Rhinitis Assessment by Molecule Type
• Allergic Rhinitis by Stage and Molecule Type

DelveInsight's Allergic Rhinitis Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Allergic Rhinitis product details are provided in the report. Download the Allergic Rhinitis pipeline report to learn more about the emerging Allergic Rhinitis therapies at:
https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Allergic Rhinitis Therapeutics Market include:
Key companies developing therapies for Allergic Rhinitis are - Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, and others.

Allergic Rhinitis Pipeline Analysis:
The Allergic Rhinitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Rhinitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Rhinitis Treatment.
• Allergic Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Allergic Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Rhinitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Allergic Rhinitis drugs and therapies-
https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Allergic Rhinitis Pipeline Market Drivers
• Increase in the prevalence of various form of allergic rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Allergic Rhinitis Market.

Allergic Rhinitis Pipeline Market Barriers
• However, high competition from generic drugs, side-effects associated with the allergic rhinitis treatment and other factors are creating obstacles in the Allergic Rhinitis Market growth.

Scope of Allergic Rhinitis Pipeline Drug Insight
• Coverage: Global
• Key Allergic Rhinitis Companies: Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others
• Key Allergic Rhinitis Therapies: EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others
• Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies
• Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers

Request for Sample PDF Report for Allergic Rhinitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Allergic Rhinitis Report Introduction
2. Allergic Rhinitis Executive Summary
3. Allergic Rhinitis Overview
4. Allergic Rhinitis- Analytical Perspective In-depth Commercial Assessment
5. Allergic Rhinitis Pipeline Therapeutics
6. Allergic Rhinitis Late Stage Products (Phase II/III)
7. Allergic Rhinitis Mid Stage Products (Phase II)
8. Allergic Rhinitis Early Stage Products (Phase I)
9. Allergic Rhinitis Preclinical Stage Products
10. Allergic Rhinitis Therapeutics Assessment
11. Allergic Rhinitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Allergic Rhinitis Key Companies
14. Allergic Rhinitis Key Products
15. Allergic Rhinitis Unmet Needs
16 . Allergic Rhinitis Market Drivers and Barriers
17. Allergic Rhinitis Future Perspectives and Conclusion
18. Allergic Rhinitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Allergic Rhinitis Market https://www.delveinsight.com/report-store/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Allergic Rhinitis Epidemiology https://www.delveinsight.com/report-store/allergic-rhinitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Allergic Rhinitis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Addison's Disease Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Cardiac Monitoring System Market: https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
• Medical Sterilization Equipment Market: https://www.delveinsight.com/report-store/medical-sterilization-equipment-market
• Tinnitus Market: https://www.delveinsight.com/report-store/tinnitus-medical-devices-market
• Vutrisiran Market: https://www.delveinsight.com/report-store/vutrisiran-market
• Microscopy Device Market: https://www.delveinsight.com/report-store/microscopy-device-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Allergic Rhinitis Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharma here

News-ID: 3818920 • Views:

More Releases from DelveInsight Business Research

Yellow Fever Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight by DelveInsight
Yellow Fever Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluat …
(Las Vgas, Nevada, United States) As per DelveInsight's assessment, globally, Yellow Fever pipeline constitutes 3+ key companies continuously working towards developing 3+ Yellow Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Yellow Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers
Influenza A Infections Market Positioned for Accelerated Development Through 2034, DelveInsight Finds
Influenza A Infections Market Positioned for Accelerated Development Through 203 …
The Influenza A Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics. DelveInsight's "Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A
Glioblastoma Multiforme Market Set for Robust Expansion Through 2034, DelveInsight Reports
Glioblastoma Multiforme Market Set for Robust Expansion Through 2034, DelveInsig …
DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Glioblastoma Multiforme market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioblastoma Multiforme Market Forecast https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Aplastic Anemia Market Growth to Surge During Forecast Period (2024-2034), Says DelveInsight
Aplastic Anemia Market Growth to Surge During Forecast Period (2024-2034), Says …
DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Allergic

Prominent Allergic Rhinitis Market Trend for 2025: Advancements In Treating Nasa …
Which drivers are expected to have the greatest impact on the over the allergic rhinitis market's growth? Anticipated growth in the allergic rhinitis market is predicted to be driven by increasing levels of air pollution and the impact of climate change. The term air pollution denotes the existence of harmful substances in our planet's atmosphere, which can negatively impact human health, damage the environment, and reduce the air's quality. Climate change
Allergic Rhinitis: A Comprehensive Overview
Allergic rhinitis, commonly known as hay fever, is a condition where an individual's immune system overreacts to allergens in the air. These allergens, which may include pollen, dust, or pet dander, trigger inflammation inside the nose, leading to symptoms like sneezing, a runny nose, itchy eyes, and congestion. While often associated with the spring and fall seasons due to pollen levels, allergic rhinitis can affect individuals year-round, depending on the
Allergic Conjunctivitis Market Statistics, Growth | Forecast
The new report published by The Business Research Company, titled ""Allergy Conjunctivitis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the allergy conjunctivitis market size has grown strongly in recent years. It will grow from $2.4 billion in 2023
Anti-Allergic Drugs Market Overview 2030
Anti-allergic drugs represent a pivotal domain in healthcare, providing advanced solutions to alleviate symptoms triggered by allergens. With an ever-growing prevalence of allergies globally, the anti-allergic drugs market is witnessing a significant surge. Valued at USD 26,234 Million in 2021, the market is poised to skyrocket to USD 47,566 Million by 2030, showcasing a robust CAGR of 6.8%. In the United States alone, where allergies affect 40 to 50 million
Allergic Conjunctivitis Market - Clear Eyes, Allergy-Free: Allergic Conjunctivit …
Newark, New Castle, USA: The "Allergic Conjunctivitis Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Allergic Conjunctivitis Market: https://www.growthplusreports.com/report/allergic-conjunctivitis-market/7892 This latest report researches the industry structure, sales, revenue,
Allergic Conjunctivitis Market - Empowering Eyes, Enhancing Lives: Redefining Al …
Newark, New Castle, USA - new report, titled Allergic Conjunctivitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Allergic Conjunctivitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Allergic Conjunctivitis market. The report offers an overview of the market, which